. Author manuscript; available in PMC: 2012 Sep 18.

Published in final edited form as: Curr Opin Urol. 2012 May;22(3):197–202. doi: 10.1097/MOU.0b013e3283519ad5

Table 1.

Selected prostate cancer immunotherapy agents and trials

Agent	Mechanism/target	Phase III studies	Phase II studies
Sipuleucel-T	Autologous cellular immunotherapy – PAP directed	Completed	Combination with abiraterone acetate (NCT01487863); sequencing with androgen ablation (NCT01431391)
Ipilimumab	Fully human anti-CTLA-4 monoclonal antibody	Prechemo (NCT00861614); postchemo (+ XRT) (NCT01057810)	Neoadjuvant (NCT01194271); combination with androgen ablation (NCT01377389)
ProstVac-VF	PSA-encoding poxvirus prime/boost regimen	Prechemo (NCT01322490)	Sequencing with docetaxel chemotherapy (NCT01145508); combination with flutamide (NCT00450463)
pTVG-HP	PAP-encoding DNA vaccine	N/A	Priming doses followed by personalized versus fixed boost regimen (NCT00849121); comparison with GM-CSF (NCT01341652)
¹⁷⁷Lu-J591	Radiolabeled monoclonal antibody to PSMA	N/A	Combination with Docetaxel (NCT00916123); combination with Ketoconazole in nonmetastatic CRPC (NCT00859781); dose escalation study (NCT00538668)

CRPC, castration-resistant prostate cancer; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4; GM-CSF, granulocyte macrophage colony-stimulating factor; PAP, prostatic acid phosphatase; PSA, prostate-specific antigen; PSMA, prostate specific membrane antigen; XRT, radiation therapy. For current information, consult www.clinicaltrials.gov.